Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
352 stopped studies mapped to Anaplastic Malignant Neoplasm and descendants · 88% state a reason
Over the 352 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00761280 | Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic…(SAPPHIRE) | Phase 3 | terminated | Sep 29, 2008 | Isarna Therapeutics GmbH | Unable to recruit the projected patient number. All analyses are descriptive, only. | Enrollment / accrual |
| NCT01088763 | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or… | Phase 1 | terminated | Mar 17, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00589095 | Early Detection of Glioblastoma Multiforme (GBM) Treatment Responses Using Multiple… | — | terminated | Jan 9, 2008 | Yale University | not stated | Not stated |
| NCT00365274 | SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic… | Phase 2 | terminated | Aug 17, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02055196 | Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With… | Phase 1 | withdrawn | Feb 5, 2014 | City of Hope Medical Center | New study written | Other (stated, no rule matched) |
| NCT01169415 | Effects of Steroid Tapering on Functional Capacity and Neurocognition | N/A | withdrawn | Jul 26, 2010 | Duke University | Funding not obtained | Funding |
| NCT01403285 | Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma | Phase 1 | terminated | Jul 27, 2011 | Immatics Biotechnologies GmbH | Due to poor accrual. This decision was taken without any safety reasons. Since beginning of the… | Safety / toxicity |
| NCT00933985 | Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane… | Phase 1 | terminated | Jul 8, 2009 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00096005 | Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | Phase 1 | terminated | Nov 9, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00101205 | Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or… | Phase 1 | terminated | Jan 10, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01854099 | Peptide Vaccine for Glioblastoma Against Cytomegalovirus Antigens(PERFORMANCE) | Phase 1 | withdrawn | May 15, 2013 | University of Florida | Investigator decided not to open study. | Investigator |
| NCT00003292 | S9624 Ifosfamide in Treating Patients With Meningeal Tumors | Phase 2 | terminated | Jan 27, 2003 | SWOG Cancer Research Network | lack of accrual | Enrollment / accrual |
| NCT01205334 | Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme(COGLI) | Phase 1 / Phase 2 | terminated | Sep 20, 2010 | Baylor College of Medicine | poor accrual | Enrollment / accrual |
| NCT01115036 | A Panobinostat Presurgery(CLBH589C) | Phase 2 | withdrawn | May 3, 2010 | Duke University | No subjects were enrolled on this study, so study was closed and IND withdrawn. | Enrollment / accrual |
| NCT01095094 | Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade… | Phase 2 | terminated | Mar 29, 2010 | Case Comprehensive Cancer Center | Study did not meet its primary objective | Other (stated, no rule matched) |
| NCT00103272 | 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With… | Phase 1 | terminated | Feb 8, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00354185 | PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic… | Phase 1 | terminated | Jul 20, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00801918 | Denileukine Diftitox for Relapsed ALCL | Phase 2 | withdrawn | Dec 4, 2008 | Columbia University | Lack of funding | Funding |
| NCT01011231 | Study of Gamma-Knife Radiosurgery Using Magnetic Resonance Imaging (MRI) Spectroscopy for…(GKS) | Phase 2 | terminated | Nov 11, 2009 | University of California, San Francisco | low accrual | Enrollment / accrual |
| NCT00650949 | Efficacy Study of CYT997 in Combination With Carboplatin in Glioblastoma | Phase 1 / Phase 2 | terminated | Apr 2, 2008 | Gilead Sciences | Strategic | Sponsor / business decision |
| NCT00959946 | Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic… | Phase 1 / Phase 2 | terminated | Aug 17, 2009 | Pfizer | not stated | Not stated |
| NCT00735436 | A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM) | Phase 2 | terminated | Aug 15, 2008 | Duke University | Study enrollment was halted due to slow accrual. | Enrollment / accrual |
| NCT01269411 | RO4929097 in Treating Patients With Recurrent Invasive Gliomas | Phase 1 | terminated | Jan 4, 2011 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00005856 | Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | Phase 1 / Phase 2 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00006773 | Bortezomib in Treating Patients With Recurrent Glioma | Phase 1 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00075491 | Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating… | Phase 2 | terminated | Jan 12, 2004 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00110032 | Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of… | Phase 1 | terminated | May 4, 2005 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00430079 | Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or… | N/A | terminated | Feb 1, 2007 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00797940 | Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy…(CLARITY-1) | Phase 2 | withdrawn | Nov 25, 2008 | Sophiris Bio Corp | No funding for study | Funding |
| NCT00734864 | Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma | Phase 1 | withdrawn | Aug 14, 2008 | Annick Desjardins | Study drug supplier withdrew support for the study. Study was withdrawn from the Duke IRB. | Other (stated, no rule matched) |
| NCT00948389 | Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM) | Phase 1 / Phase 2 | terminated | Jul 29, 2009 | Bristol-Myers Squibb | Inability to meet protocol objectives | Other (stated, no rule matched) |
| NCT00272870 | Treatment of Newly Diagnosed Brain Tumors With Chemotherapy and Radiation Using Cells… | Phase 1 | terminated | Jan 9, 2006 | Children's Hospital Medical Center, Cincinnati | Slow accrual; drug availability | Drug supply |
| NCT00704691 | Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell… | Early Phase 1 | terminated | Jun 25, 2008 | University of Alabama at Birmingham | Closed due to futility with only 1 patient accrued | Efficacy / futility |
| NCT01044225 | Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on… | Phase 2 | terminated | Jan 7, 2010 | Bart Neyns | Results of the phase III RTOG0525 trial made the manufacturer of cilengitide decide to end their… | Drug supply |
| NCT01189513 | SCH-900105 in Recurrent Glioblastoma | Phase 1 | withdrawn | Aug 26, 2010 | M.D. Anderson Cancer Center | Sponsor decision. | Sponsor / business decision |
| NCT00508456 | Dietary Methionine Restriction Plus Temozolomide for Recurrent GBM | Phase 1 | terminated | Jul 30, 2007 | M.D. Anderson Cancer Center | Low Accrual | Enrollment / accrual |
| NCT01105988 | Evaluating Tumor Pseudoprogression With FLT-PET and MRI | Early Phase 1 | terminated | Apr 19, 2010 | Massachusetts General Hospital | Funding ended | Funding |
| NCT01441388 | A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid… | Phase 1 | withdrawn | Sep 27, 2011 | Pfizer | Business/Operational issues | Sponsor / business decision |
| NCT00790452 | Aspirin Prophylaxis for Venous Thromboembolism in Glioblastoma | Phase 2 | terminated | Nov 13, 2008 | M.D. Anderson Cancer Center | Low accrual. | Enrollment / accrual |
| NCT00515086 | Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM) | Phase 2 | terminated | Aug 13, 2007 | Novartis Pharmaceuticals | Early termination due to slow enrollment and protocol-defined stopping rule. | Enrollment / accrual |
| NCT00062504 | Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas | Phase 2 | terminated | Jun 12, 2003 | Teva Branded Pharmaceutical Products R&D, Inc. | not stated | Not stated |
| NCT00290771 | Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent… | Phase 2 | terminated | Feb 13, 2006 | Novartis | Lack of efficacy | Efficacy / futility |
| NCT00615186 | Glioblastoma Multiforme (GBM) Locoregional Agent Survival Study - Anti-tenascin…(Glass-Art) | Phase 3 | terminated | Feb 14, 2008 | Bradmer Pharmaceuticals Inc. | Due to delay in site initiation and funding considerations | Funding |
| NCT01116154 | Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin… | Phase 1 | terminated | May 4, 2010 | City of Hope Medical Center | Sponsor withdrew support for the study | Other (stated, no rule matched) |
| NCT00243490 | Photodynamic Therapy in the Treatment of Malignant Intracranial Tumors | Phase 2 | withdrawn | Oct 24, 2005 | National Taiwan University Hospital | The Trial could not get permit from Department of Health, Taiwan; Furthermore, no research fund… | Funding |
| NCT00730262 | Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme | Phase 2 | terminated | Aug 8, 2008 | Thallion Pharmaceuticals | Lack of efficacy | Efficacy / futility |
| NCT00376103 | Radiation Boost for Newly Diagnosed Glioblastoma Multiforme | Phase 1 / Phase 2 | terminated | Sep 14, 2006 | Methodist Healthcare - Memphis | Loss of funding from sponsor | Funding |
| NCT00548938 | Gliadel Wafer, Temozolomide and Radiation Therapy for Newly Diagnosed GBM | Phase 2 | terminated | Oct 24, 2007 | Methodist Healthcare - Memphis | Principal Investigator has left the institution | Investigator |
| NCT00904852 | Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After… | Phase 1 | withdrawn | May 20, 2009 | Millennium Pharmaceuticals, Inc. | not stated | Not stated |
| NCT00365222 | Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma | Phase 2 | terminated | Aug 17, 2006 | H. Lee Moffitt Cancer Center and Research Institute | IRB Study Closure | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Nov 14, 2014source: clinicaltrials